Drugs / [11C]TASP0410699
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02448212 | May 2015 → Jan 2016 | — | Taisho Pharmaceutical R&D Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]TASP0410699 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02448212 ↗ |
| Modality | Diagnostic / imaging agent | “novel tracer” NCT02448212 ↗ |
| Route | Intravenous | “Intravenous radiotracer” NCT02448212 ↗ |